Same pill, different person: a gentle intro to pharmacogenetics
You have already run a pharmacogenetics experiment on yourself. If coffee after lunch wrecks your sleep while your friend orders espresso at dinner, you have watched two genomes process the same drug at different speeds. Caffeine is handled mostly by the liver enzyme CYP1A2, nicotine by CYP2A6, alcohol by ADH and ALDH2, and each of those enzymes comes in faster and slower genetic versions. The differences are real, measurable, and, for these everyday molecules, safely useful to know.
Pharmacogenetics is that same idea applied to medications, and it is where consumer genetics needs its most honest boundaries.
The real science
The core mechanism is not controversial. A large share of prescription drugs is processed by a small family of liver enzymes, and common variants make some of those enzymes run fast, slow, or barely at all. Slow processing can mean a standard dose behaves like a large one; ultra-fast processing can mean a drug barely gets a chance to work. For a number of drug-gene pairs the evidence has matured into formal clinical guidelines that hospitals actually use, with dosing adjusted after a clinical-grade genetic test.
That is the key phrase: clinical-grade. Serious pharmacogenetic decisions run on dedicated tests, ordered and interpreted by clinicians, because the stakes are real and because consumer chips were not built for that job.
What a wellness report can honestly offer
Research literature also links common markers to how people respond to dozens of medications, from antidepressants to statins, and some of those markers sit in your raw file. We include a set of them in your report, labeled bluntly as what they are: research-stage signals, context for a conversation, never an instruction. The rules we follow, and that you should demand from any report:
- Nothing in a wellness report is a reason to start, stop, or re-dose any medication. That decision path runs through your prescriber, possibly via a clinical pharmacogenetic test.
- Research-stage means exactly that: interesting cohort findings, often modest samples, awaiting the replication bar that the everyday traits in this blog have already cleared.
- The everyday pharmacology, caffeine, alcohol, nicotine, is fair game for self-experiments, because you already run those experiments daily, just without the data.
Why we think it belongs in your report anyway
Because "ask your doctor" works better with a starting point. A patient who can say "my report flags a research-stage signal on this drug class, is that worth a proper test?" asks a sharper question than one who brings nothing, and clinicians can order the real thing when it matters.
Your Helisoma report keeps the two worlds visibly separate: everyday metabolism traits you can act on at breakfast, and research-stage medication signals filed under talk-to-a-professional. Connect it to your AI assistant, and it will hold that line too, we made sure.
Sources
- CYP1A2 and caffeine metabolism. PubMed 29514871
- CYP2A6 variants and nicotine clearance. PubMed 22046326
- CPIC, the Clinical Pharmacogenetics Implementation Consortium guidelines. cpicpgx.org